title: Menopausal Hormone Therapy, Age, and Chronic Diseases: Perspectives on Statistical Trends.
abstract: The release of the Women's Health Initiative (WHI) study in 2002 was a shock to the medical community. Hormone therapy (HT) had generally been considered to be highly beneficial for postmenopausal women since it was the gold standard for relief of menopausal symptoms (hot flashes, night sweats, vaginal atrophy) and it was thought to protect women from osteoporosis, heart disease, and cognitive decline and to generally improve quality of life. However, WHI showed a statistically significant increase in a number of disease states, including breast cancer, cardiovascular disease, and stroke. One problem with the WHI study was that the average age of women in the study was 63, which is considerably older than the age at which most women enter menopause (about 51). The timing hypothesis attempts to rationalize the effect of age on response to HT and risk of various diseases. The data suggests that younger women (50-60) may be protected from heart disease with only a slight increase in breast cancer risk. In contrast, older women (>65) are more susceptible to breast cancer and heart disease and should avoid HT. This Perspective on Statistical Trends evaluates the current data on HT and risk for chronic diseases as a function of age.
authors.affiliation: Department of Medicinal Chemistry and Pharmacognosy (M/C 781) College of Pharmacy, University of Illinois at Chicago , 833 S. Wood St., Chicago, Illinois 60612-7231, United States.
authors.forename: Judy L
authors.initials: JL
authors.lastname: Bolton
mesh_terms: D000367:Age Factors; D001943:Breast Neoplasms / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D020521:Stroke / Q000188:drug therapy*